Accelerating the Development of Biologic Therapeutics through Advanced Analytics
BioAnalytix is developing and applying advanced analytic methods and data to enable, improve and accelerate biologic therapeutics from development through market
What We Do
BioAnalytix is a pharmaceutically oriented spin-out from the Barnett Institute of Chemical and Biological Analysis at Northeastern University. Founded in 2012 by thought leaders in biologic drug development, regulatory strategy, and advanced analytics, BioAnalytix works with leading pharmaceutical companies to develop and apply advanced analytic technologies, methods and data in enabling, improving and accelerating biologic therapeutics from development through market.
BioAnalytix Announces Poster Presentations of Advanced HDX-MS, LC-MS HCP Analysis and Top-Down Disulfide Mapping Approaches in Biopharmaceutical Development
Washington, DC – (January 24-26, 2017) – BioAnalytix and leading pharmaceutical companies present advanced approaches and findings at Well Characterized Biologic Pharmaceuticals Meeting.
Mapping Critical Quality Attributes of a Biopharmaceutical In Vivo by Unique Affinity Purification and Advanced LC-MS Methods
Washington, DC – (January 27, 2017) – BioAnalytix announces poster presentation of advanced In Vivo CQA Mapping approaches in biopharmaceutical development. Full Abstract »